Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Artara Therapeutics Inc (TARA)

Artara Therapeutics Inc (TARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,196
  • Shares Outstanding, K 20,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,420 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.36

Options Overview Details

View History
  • Implied Volatility 94.66% ( -31.79%)
  • Historical Volatility 190.00%
  • IV Percentile 34%
  • IV Rank 13.81%
  • IV High 559.87% on 11/20/24
  • IV Low 20.12% on 09/17/24
  • Put/Call Vol Ratio 7.90
  • Today's Volume 89
  • Volume Avg (30-Day) 1,493
  • Put/Call OI Ratio 1.78
  • Today's Open Interest 4,796
  • Open Int (30-Day) 5,757

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.56
  • Number of Estimates 2
  • High Estimate -0.54
  • Low Estimate -0.59
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +37.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.36 +121.97%
on 11/25/24
10.48 -50.10%
on 12/05/24
+2.84 (+118.83%)
since 11/22/24
3-Month
1.60 +227.90%
on 10/10/24
10.48 -50.10%
on 12/05/24
+3.34 (+176.72%)
since 09/23/24
52-Week
1.60 +227.90%
on 10/10/24
10.48 -50.10%
on 12/05/24
+3.40 (+185.79%)
since 12/22/23

Most Recent Stories

More News
Protara Therapeutics Closes $100 Million Public Offering to Fund Clinical Development

Protara Therapeutics closed a $100 million public offering to fund clinical development of its therapies.Quiver AI SummaryProtara Therapeutics, Inc. announced the completion of its public offering of 13,690,000...

TARA : 5.22 (-3.15%)
Protara Announces Closing of $100 Million Public Offering

TARA : 5.22 (-3.15%)
Protara Therapeutics Announces Commencement of Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Protara Therapeutics announced a public offering of common stock to fund clinical development programs.Quiver AI SummaryProtara Therapeutics, Inc. has announced the initiation of an underwritten public...

TARA : 5.22 (-3.15%)
Protara Announces Pricing of $100 Million Public Offering

TARA : 5.22 (-3.15%)
Protara Announces Proposed Public Offering

TARA : 5.22 (-3.15%)
Protara Therapeutics Reports Positive Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer

TARA-002 shows promising response rates in NMIBC patients, with favorable safety and tolerability in a Phase 2 trial.Quiver AI SummaryProtara Therapeutics, Inc. announced promising results from its Phase...

TARA : 5.22 (-3.15%)
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes

The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.

TARA : 5.22 (-3.15%)
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

TARA : 5.22 (-3.15%)
Protara Therapeutics Announces Conference Call to Discuss Interim Analysis of TARA-002 in Phase 2 NMIBC Trial

Protara Therapeutics will present interim Phase 2 trial data for TARA-002 in NMIBC on December 5, 2024.Quiver AI SummaryProtara Therapeutics, Inc. announced that it will host a conference call and live...

TARA : 5.22 (-3.15%)
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

TARA : 5.22 (-3.15%)

Business Summary

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an...

See More

Key Turning Points

3rd Resistance Point 5.93
2nd Resistance Point 5.67
1st Resistance Point 5.53
Last Price 5.22
1st Support Level 5.13
2nd Support Level 4.87
3rd Support Level 4.73

See More

52-Week High 10.48
Fibonacci 61.8% 7.09
Fibonacci 50% 6.04
Last Price 5.22
Fibonacci 38.2% 4.99
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar